Background: Patients with chronic kidney disease (CKD) often have CD4þ regulatory T cells (Tregs) dysfunction and chronic inflammation. We aim to investigate the effect, function, and related mechanism of low-dose IL-2 on CD4 þ regulatory T cells expansion in vitro from patients with CKD. Methods: A total of 148 newly diagnosed patients with CKD at Stage III and 35 healthy volunteer subjects were recruited into our studies. The number of peripheral Tregs in peripheral blood mononuclear cells isolated from CKD patients, which were characterized by FACS as CD4 þ CD25
Low-dose IL-2 expands CD4
þ regulatory T cells with a suppressive function in vitro via the STAT5-dependent pathway in patients with chronic kidney diseases Background: Patients with chronic kidney disease (CKD) often have CD4þ regulatory T cells (Tregs) dysfunction and chronic inflammation. We aim to investigate the effect, function, and related mechanism of low-dose IL-2 on CD4 þ regulatory T cells expansion in vitro from patients with CKD. Methods: A total of 148 newly diagnosed patients with CKD at Stage III and 35 healthy volunteer subjects were recruited into our studies. The number of peripheral Tregs in peripheral blood mononuclear cells isolated from CKD patients, which were characterized by FACS as CD4 þ CD25 hi and CD4 þ CD25 þ FoxP3 þ . The effect of low-dose IL-2 on expansion of Tregs, and the suppressive function of expanded Tregs were also analyzed by FACS. The levels of FoxP3 mRNA were detected by qRT-PCR. The activation of IL-2 induced Stat5 and blocking experiments were assessed by Western Blotting and FACS. Results: We found that the frequency of peripheral Tregs from CKD patients was significantly lower than that in healthy volunteer subjects. We also showed that IL-2 selectively expanded CD4 þ CD25 hi and CD4 þ CD25 þ FoxP3 þ regulatory T cells, and also upregulated the expression of FoxP3 mRNA. Our in vitro studies demonstrated that expanded CD4 þ regulatory T cells from CKD patients suppressed proinflammatory Th1 and Th17 cell response. Furthermore, STAT5 activation is required for IL-2-induced expansion of regulatory T cells and expression of FoxP3 mRNA from CKD patients. Conclusions: Our findings support the clinical Treg defects in CKD patients with glomerular diseases, and the rationale of evaluating low-dose IL-2 treatment for selectively modulating CD4 þ Tregs.
Introduction
Chronic and persistent inflammation has been recently recognized as an essential component of chronic kidney disease (CKD), it is also accountable in part for the leading causes of cardiovascular and all-cause mortality [1] . The progression of renal injury usually involves a mixture of innate and cognate processes, and both the immune responses are involved not only in kidney disease activation but also in disease regulation and progression [2] . The CD4 þ regulatory T cells (Tregs)
comprise a small proportion of the total lymphocyte population but can regulate key immune responses across various autoimmune disease settings. Tregs, which specifically express the transcription factor forkhead box P3 (FoxP3), are critical for the maintenance of self-tolerance and play an important role in controlling immune responses of effector T-cells to auto and foreign antigens; they prevent a wide range of clinical conditions such as organ-specific autoimmune diseases, and control anti-tumor responses, anti-viral responses, and immune responses to alloantigens in the setting of organ transplantation [3, 4] . They also play an important role in murine models of immune-mediated renal diseases and human glomerular diseases. Reduced suppressive function and the number of peripheral Tregs have been previously reported in autoimmune disorders including several glomerulonephropathy [5] [6] [7] [8] . However, the function of peripheral Tregs in patients with CKD has not been clarified. Interleukin-2 (IL-2) is a crucial cytokine for the function, homeostasis, and survival of CD4 þ CD25 þ FoxP3 þ regulatory T cells [9] . Currently, it is widely accepted that IL-2 plays a critical role mainly in Treg fitness and homeostasis, partially due to the constitutively high expression of CD25, which makes these cells highly IL-2-dependent. Many recent studies have revealed that low-dose IL-2 therapy preferentially expands CD4 þ regulatory T cell populations in humans; the results from these studies showed that administration of lowdose IL-2 to patients with chronic graft-versus-host disease (GVHD) [10] , autoimmune vasculitis induced by hepatitis C virus infection [11] , type I diabetes mellitus [12] , and systemic lupus erythematosus [13, 14] 
Materials and methods

Study patients and healthy volunteer
Surface and intracellular antigen staining and flow cytometry
PBMCs were isolated by density centrifugation using Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) gradient centrifugation and were then cultured. Cell surface staining was followed by incubation for 30 min on ice with CD4-FITC (BD Biosciences, San Jose, CA), and CD25PE (BD Biosciences). Intracellular cytoplasmic and nuclear antigen staining was performed using the eBiosciences FACS staining protocol, as it allows the simultaneous analysis of cell surface molecules and intracellular antigens at the single-cell level. After surface staining, fixation was followed by permeabilization, and all intracellular staining was performed using the Intracellular Fixation & Permeabilization Buffer Set (eBioscience, San Diego, CA) for the detection of cytoplasmic cytokines IFN-c and IL-17A. For the detection of nuclear protein FoxP3, the Foxp3/Transcription Factor Buffer Set (eBioscience) was used for nuclear staining. Appropriate isotype controls were included in each experiment. Flow cytometric analyzes were performed on the FACSCalibur flow cytometer (BD Biosciences) with a total of 20,000 events recorded for each sample through a CD4 þ lymphocyte gate. Analysis of flow cytometry data was performed using FlowJo software (TreeStar, Inc., Ashland, OR).
Western blotting
Equal amounts (50 mg) of total protein from treated cell lysates were separated on 10% SDS-PAGE gels. The proteins were electrophoretically transferred to a nitrocellulose membrane. After blocking in 5% nonfat milk for 1 h at room temperature, the membranes were then incubated overnight at 4 C with various primary antibodies against phospho-Stat5, Stat5 (all at 1:1000), and b-actin (1:5000). Following an extensive washing in PBS containing 0.1% Tween-20, the membranes were then incubated with a horseradish peroxidase-conjugated secondary antibody (anti-mouse at 1: 3000, anti-rabbit at 1: 3000) (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature in PBS. Membranes were then washed with PBS containing 0.1% Tween-20, and the results were obtained using the enhanced chemiluminescence system (PerkinElmer Inc., Boston, MA). After blotting of phospho-Stat5, the same membranes were stripped and reprobed with the anti-Stat5 antibodies and anti-b-Actin, respectively.
Quantitative RT-PCR 
Mixed lymphocyte reactions
We examined the effect of Tregs from CKD patients, which had been exposure to 50 unit/mL of IL-2 for 4 days on the synthesis of cytokines of Th1 and Th17 lymphocytes in mixed lymphocyte reactions (MLR) isolated from human PBMCs. The PBMCs isolated by density centrifugation from healthy donors were used as effector cells and were labeled with 10 mM CFSE (Life Technologies). Then, the CFSE-labeled cells were mixed and cocultured with the expanded CD4þ Tregs at 5:1 from CKD patients for 24 h. CFSE-labeled cells without coculture with Tregs were used as controls. At the last 4 h, phorbol myristate acetate (PMA) (50 ng/ml, SigmaAldrich) and ionomycin (500 ng/ml, Sigma-Aldrich) were added. In the last 2 h, Brefeldin A (Sigma-Aldrich) was added. The cells were collected at the end of incubation, and cell surface antigens were stained with anti-CD4-PerCP-CY5.5 (BD Biosciences). The cells were then subjected to intracellular staining with IL-17A-PE and IFN-c-APC (BD Biosciences). The stained cells were analyzed by flow cytometry.
Statistics
Data are presented as mean ± SEM from at least three independent experiments. The significance of differences between the comparative groups was analyzed using Student's t-test and one-way ANOVA analysis with SigmaStat3.5 software (Chicago, IL). Statistical significance was defined at an alpha value of p .05.
Results
The frequency of CD4 patients with CKD patients with chronic GN and healthy individuals, and the cells were analyzed by flow cytometry. As shown in Figure 1 , the frequencies of regulatory T cells from CKD patients that were identified as CD4 þ CD25 hi (Figure 1(a) ) and
were significantly lower than those in normal individuals. However, the percentages of lymphocytes and CD4 þ T cells in the PBMCs of CKD patients were comparable to those of normal subjects, as shown in Figure 1 (c). Our data indicate for the first that the numbers of CD4 þ regulatory T cells from PBMCs of CKD patients declined, even though the percentages of lymphocytes and CD4 þ T cells were sustained at the same levels like that in PBMCs from normal subjects.
Low-dose IL-2 specifically expands CD4 1
regulatory T cells in PBMCs from CKD patients
Most recently, low-dose IL-2 has also been shown to expand or modify CD4 þ regulatory T cells in vitro from patients with SLE [13, 14] and children with the drugresistant idiopathic nephrotic syndrome [19] . We aimed to confirm whether low-dose recombinant human IL-2 (rhIL-2) can expand Tregs in vitro in PBMCs from CKD patients. The dosages of rhIL-2 at 25, 50, and 100 IU/ml were chosen according to a previous report [9] , in which IL-2 concentration <100 IU/ml was considered to be low for the in vitro study. PBMCs from 28 patients with CKD were randomly divided into four groups treated with rhIL-2 at 0, 25, 50 and 100 IU/ml concentrations for 4 days, respectively. After 4 days, the PBMCs were collected, and CD4 þ CD25 þ Foxp3 þ Tregs were analyzed by FACS (Figure 2(a) ). Compared with the untreated control (0 IU/ml) group of PBMCs, IL-2 treatments at 25, 50 and 100 IU/ml significantly induced expansion of CD4 þ CD25 þ Foxp3 þ Tregs, and $70% more Tregs were expanded by all three doses of IL-2 compared with untreated cells (Figure 2(b) ). Because the volume of venous blood for examination of FoxP3 in PBMCs from CKD patients was limited, we collected additional blood samples from 44 patients with CKD, which were randomly divided into four groups. The isolated PBMCs were treated with IL-2 at 0, 25, 50 and 100 IU/ml for 4 days, respectively, and the percentage of CD4 þ CD25 hi Tregs was analyzed. As shown in Figure   2 (c), CD4 þ CD25 hi Treg expansion was induced by IL-2 as compared with untreated cells. Furthermore, the effects of rhIL-2 on Treg expansion were dose-dependent; nearly 250% more Tregs were expanded by 50 and 100 IU/ml of IL-2 compared with the untreated cells. We also confirmed the same findings as in previous reports [13, 14] that low-dose IL-2 treatment did not expand CD4 þ CD25-effector T cells in PBMCs from CKD patients (Figure 2(d) ). Together, these results show for the first time that low-dose IL-2 treatment in PBMCs from CKD patients specifically expands Tregs in vitro, and these results imply that low-dose IL-2 administration could modify endogenous peripheral Tregs from CKD patients.
Low-dose IL-2-expanded regulatory T cells from CKD patients suppress the production of Th1 and Th17 cytokines in PBMCs
Multiple studies have identified CD4 þ helper T cells, Th1 and Th17, as the central players of GN. Th1 and Th17 responses cause renal tissue damage, while Tregs mediate protection [20] . This prompted us to ask whether the low-dose IL-2-expanded regulatory T cells have a suppressive function on the production of cytokines of effector Th1 and Th17 cells in vitro. As shown in Figure 3 , when PBMCs from normal subjects were cocultured with expanded CD4 þ CD25 high regulatory T cells from CKD patients, a significant decrease in the percentage of IFN-c þ Th1 (Figure 3(a) ) and IL-17A þ T lymphocytes are depicted in the graph. p Values are depicted in the graph. Study groups were compared using the nonparametric Student's t-test. Ã p < .05, ÃÃ p < .01, NS: no significance, for comparisons between the CKD patients group and the healthy controls using t-tests. þ T cells are depicted in a graph (n ¼ 18). p Values are depicted in the graph. Ã p < .05, ÃÃ p < .01 for comparisons between the CKD patients group and healthy controls using one-way ANOVA.
Taken together, our data strongly support the possibility of using ex vivo-expanded natural Tregs as a cellular therapy for CKD patients with chronic GN.
Low-dose IL-2 alter the expression of Foxp3 mRNA in stimulated PBMCs
Because the transcription factor FoxP3 is the master regulator for the regulatory T cell lineage and levels of Foxp3 expression have been interpreted primarily to reflect Treg frequency [21] , we further analyzed the Foxp3 mRNA levels of IL-2-expanded Tregs. In this study, we chose a dose of 50 IU/ml IL-2 to stimulate PBMCs from 10 patients for 4 days and detected the frequency of CD4 þ CD25 hi Tregs by FACS and mRNA expression of FoxP3 by real-time qRT-PCR. We found that the levels of FoxP3 mRNA increased significantly compared to the no IL-2 stimulation control, as illustrated in Figure 4 , and the magnitude of increase in FoxP3 mRNA levels was similar to the increase in the frequency of CD4 þ CD25 hi Tregs. Our data indicate that low-dose IL-2 could stimulate the production of Tregs ex vivo by inducing FoxP3 mRNA expression.
STAT5 phosphorylation is required for low-dose IL-2-induced expansion of CD4 1 regulatory T cells and expression of FoxP3 mRNA in PBMCs
Several studies have supported a role of STAT5 signaling in IL2-induced regulatory T cell development from patients with different illness [22, 23] . However, the role of STAT5 in regulatory T cell production in CKD patients is unknown. We investigated the effect of low-dose IL-2 on the phosphorylation of STAT5 in expanded Tregs from CKD patients. As shown in Figure 5 (a), IL-2 remarkably stimulated STAT5 phosphorylation in PBMCs from CKD patients. Pimozide is a specific inhibitor of STAT5 phosphorylation, and we examined its effect on STAT5 phosphorylation by pretreating cells with it. As seen in Figure 5 (b), 3 mM pimozide pretreatment dramatically suppressed IL-2-induced STAT5 phosphorylation, indicating that it is a potent blocker of IL-2-stimulated STAT5 phosphorylation in PBMCs from CKD patients. We further tried to determine whether inhibition of STAT5 activation could abrogate low-dose IL-2-mediated FoxP3 mRNA expression and Treg expansion in PBMCs from patients with CKD. Pimozide pretreatment significantly suppressed IL-2-induced expression levels p Values are depicted in the graph. Ã p < .05, ÃÃ p < .01 for comparisons between the IL-2 treated group and the non-IL-2 treated group using t-tests.
of FoxP3 mRNA (Figure 6(a) ), as well as the markedly decreased IL-2-stimulated expansion of CD4 þ CD25 þ Foxp3 þ T regulatory cells (Figure 6(b) ).
These results demonstrate that low-dose IL-2 promotes the generation of CD4 [26] and decrease infiltration of inflammatory cells and proteinuria in CKD animal models [27] . Our data also documented an important role of STAT5 activation for IL-2 and in shaping the development of peripheral Tregs in patients with CKD, together with other studies have demonstrated that IL-2 and STAT5 play critical roles in maintaining the stability and function of the peripheral Treg lineage [23] . Dysregulated systemic helper T cell Th1 and Th17 immunity was proven to be central to the development of kidney injury in renal inflammatory diseases, initiation of human GN, and animal GN model [20, 28] . In contrast to pathogenic Th1 and Th17 responses, regulatory T cells (Tregs) were proven to be inhibitors of various effector T cells such as IFNc-producing Th1 cells and the recently identified IL-17 þ T helper 17 (Th17) cells in GN [29] . This new and evolving field of cellular therapy would allow for the use of functional Treg cells that have the capacity to suppress both potentially pathogenic Th1 and Th17 cells and is an attractive option for treating immune-mediated kidneys shortly.
In conclusion, our present study demonstrated for the first time that low-dose IL-2 can expand CD4 þ CD25 þ FoxP3 þ Tregs preferentially via the STAT5 pathway in PBMCs from CKD patients with chronic glomerular diseases in vitro, and the expanded Tregs exert potential suppressive function on the production of proinflammatory Th1 and Th17 cytokines. Our data implied that low-dose IL-2 therapy has a promising role in the treatment of CKD patients with chronic glomerular diseases as a novel, effective, and safe therapeutic approach. 
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